Pluvicto (extended indications)
Evidence Grade B — Strong clinical evidence. 172 published studies, 122 human. 85 registered clinical trials.
This entry covers the investigational use of Pluvicto (lutetium-177 vipivotide tetraxetan) in earlier stages of prostate cancer than its current approval. Pluvicto is already approved for late-stage prostate cancer (see the separate Pluvicto entry); trials are now investigating whether using it earlier in the disease course — when tumours may be more responsive — produces better outcomes.
172 published studies: 122 human, 0 animal, 5 in-vitro, 26 reviews
Pluvicto is approved for late-stage prostate cancer (see compound #66). Extended-indication trials are investigating use in earlier disease stages. The PSMAfore trial (468 patients) showed significantly improved progression-free survival in pre-taxane patients. The PSMAddition trial is investigating combination with standard hormonal therapy in metastatic hormone-sensitive prostate cancer.
The strategic question is whether moving radioligand therapy earlier in the treatment sequence — when patients have less advanced disease and potentially more PSMA-expressing tumour cells — produces better outcomes. This is not a peptide.
The PSMA-617 ligand binds to prostate-specific membrane antigen (PSMA) on cancer cells. Upon binding, the construct is internalised into the cell, delivering targeted radiation that destroys the cancer cell while minimising damage to surrounding tissue. The investigation of earlier treatment lines aims to determine whether this targeted radiation approach is more effective when used before extensive prior therapy.
The PSMAfore trial (468 patients) showed significantly improved progression-free survival in patients who had not yet received chemotherapy, leading to an expanded FDA approval in March 2025. The larger PSMAddition trial is testing Pluvicto in combination with standard hormone therapy in newly diagnosed metastatic prostate cancer — a setting that could potentially double the eligible patient population. Key safety considerations include dry mouth (38-61%), bone marrow suppression, and the requirement for PSMA-PET imaging to confirm eligible patients. Manufacturing and supply chain constraints for the radioactive component (lutetium-177) remain a practical limitation. The strategic question is whether radioligand therapy earlier in the treatment sequence produces meaningfully different outcomes than its current late-stage use.
177Lu-PSMA-617 Managed Access Program for mCRPC Patients
Lu-177 PSMA Treatment in Cell Renal Carcinoma
177Lu-PSMA-617 With Liver Directed Therapy in Metastatic Castration Resistant Prostate Cancer
177^Lu-PSMA-617 in Combination With Sipuleucel-T for the Treatment of Metastatic Castration-Resistant Prostate Cancer
Alpha-Emitting Radionuclide or Beta-Emitting Radionuclide With Metastasis-Directed Stereotactic Body Radiotherapy for the Treatment of Recurrent, Oligometastatic Prostate Adenocarcinoma
FDA ORIG 1
EMA Marketing Authorisation
FDA SUPPL 24
FDA SUPPL 21
The information on this page is provided for educational and research reference purposes only. This is not medical advice. Always consult a qualified healthcare professional before making any health-related decisions.
Exenatide was the first GLP-1 receptor agonist approved anywhere, reaching the market as Byetta in April 2005. The once-weekly formulation Bydureon followed in 2012. Clinical trials showed blood sugar reductions (HbA1c) of 1.6–1.9% and modest weight loss of 2–4 kg. The EXSCEL cardiovascular outcomes trial, involving over 14,700 patients, showed a trend toward cardiovascular benefit but narrowly missed statistical significance. While exenatide was groundbreaking as the first in its class, it has been largely overtaken by newer GLP-1 treatments that offer greater efficacy, less frequent dosing, and proven cardiovascular benefits. It remains available and in clinical use, particularly in combination products.
Lixisenatide was marketed as Adlyxin in the US (approved July 2016), though it has since been discontinued in the US market. The ELIXA cardiovascular trial, involving over 6,000 patients, was the first cardiovascular outcomes trial for any GLP-1 medication to report results. It showed a neutral cardiovascular profile — neither harmful nor beneficial — meeting safety requirements but not demonstrating the heart benefits later shown by semaglutide and liraglutide. Lixisenatide found its primary clinical role in combination with basal insulin, marketed as Soliqua (lixisenatide plus insulin glargine). This combination addresses both fasting blood sugar (via insulin) and post-meal spikes (via lixisenatide) in a single daily injection. As a standalone treatment, it has been largely superseded by more potent GLP-1 medications.
Pramlintide is marketed as Symlin (approved March 2005) and remains the only approved amylin-based treatment. It is used alongside mealtime insulin in both type 1 and type 2 diabetes. Clinical trials showed modest blood sugar improvements (HbA1c reductions of 0.2–0.6%) and approximately 2.3 kg of weight loss — less dramatic than GLP-1 treatments but meaningful as an add-on therapy. Symlin carries a boxed warning for severe hypoglycaemia, particularly when combined with insulin, and requires careful dose adjustment. Practical uptake has been limited by the need for separate injections at each meal alongside existing insulin injections. Despite its modest clinical impact, pramlintide remains the only medication that addresses the amylin deficiency in diabetes, filling a distinct biological role that GLP-1 treatments do not cover.
